Leukaemia Trial, Recruiting (NCT06211166)

Leukaemia Trial, Recruiting NCT06211166 Sponsor: Peking University People's Hospital Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06211166 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who had at least one specific genetic marker (a fusion gene or blood cancer-related mutation) detected at the time of their original diagnosis, using a type of genetic testing, and where that marker is being used to monitor their cancer after transplant.
People whose body has successfully started producing new white blood cells (neutrophils) following their stem cell transplant, showing the transplant has begun to take hold.
People who have already had at least one post-transplant test using a highly sensitive method called digital PCR to check for remaining cancer cells.

Who may not be able to join:

People whose cancer came back, or who passed away, before their first digital PCR monitoring test after the transplant.
People whose only detected mutations are in genes called DNMT3A, TET2, and ASXL1 (sometimes called "DTA mutations"), or whose mutations are inherited (germline) rather than related to their cancer. (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiao-jun Huang, M.D, Peking University People's Hospital

Phone: +861088324637

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06211166

Sponsor: Peking University People's Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: +861088324637

More information: https://clinicaltrials.gov/study/NCT06211166

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who had at least one specific genetic marker (a fusion gene or blood cancer-related mutation) detected at the time of their original diagnosis, using a type of genetic testing, and where that marker is being used to monitor their cancer after transplant.
People whose body has successfully started producing new white blood cells (neutrophils) following their stem cell transplant, showing the transplant has begun to take hold.
People who have already had at least one post-transplant test using a highly sensitive method called digital PCR to check for remaining cancer cells.

Who may not be able to join:

People whose cancer came back, or who passed away, before their first digital PCR monitoring test after the transplant.
People whose only detected mutations are in genes called DNMT3A, TET2, and ASXL1 (sometimes called "DTA mutations"), or whose mutations are inherited (germline) rather than related to their cancer. (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking University People's Hospital

Registry

ClinicalTrials.gov

Start date

8 January 2024

Est. completion

31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Threshold of dPCR to predict conventional MRD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov